GRIPonMASH GRIP on MASH: Global Research Initiative for Patient Screening on MASH
- Coordinator
- Universitair Medisch Centrum Utrecht, Netherlands
- Runs
- 1 December 2023 to 30 November 2027
- Status
- Running
- EU funding
- €14.0m
- Total cost
- €26.2m
- Partners
- 40 organisations in 14 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101132946
What the project is doing
In the project's own words, from its summary on CORDIS.
GRIP on MASH will address the unmet public health need of reducing disease burden and comorbidities associated with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Together with seven medical technology, pharmaceutical and biotechnology companies, we will devise a sustainable and scalable GRIP on MASH Platform that will enable access to at-risk patients developing or having MASLD through the early detection of this condition at the primary care level.
This Platform will allow A) the early detection of patients with MASLD: distributed in 12 European Centers of Excellence (CoEs), 10,000 patients at high risk of MASLD - defined as patients with type-2 diabetes mellitus, metabolic syndrome, obesity or arterial hypertension - will be screened and characterized; B) better patients’ stratification: the Platform will comprise artificial intelligence-based decision support tools that will make use of existing and novel biomarkers/biomarker combinations.
Their predictive accuracy will be tested at the primary care level; there we will perform multi-OMICs analysis (proteomics, lipidomics, metabolomics, genomics, metagenomics and fluxomics) in fasted blood samples and we will explore imaging biomarkers/organ-on-a-chip to find future non-invasive diagnostic alternatives for the current standard (liver biopsies); and C) personalized lifestyle advice, by exploring evidence-based lifestyle features and the effect of nutritional recommendations: among the cohorts at the CoEs, we will use validated questionnaires to assess physical activity, diet, sleep, smoking, alcohol consumption, and perception of stress.
Integrating patients’ perspectives with the participation of two patient organizations, the trustworthiness and sustainability of our GRIP on MASH Platform will be assessed by investigating potential economic, ethical and regulatory barriers to its future adoption. GRIP on MASH will change healthcare practice in MASLD and reduce the disease burden for patients.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Coordinator |
| European Liver Patients Association | Bruxelles / Brussel | Belgium | Participant |
| Liver Patients International | Bruxelles / Brussel | Belgium | Participant |
| Universitair Ziekenhuis Antwerpen | Edegem | Belgium | Participant |
| Universite Libre De Bruxelles | Bruxelles | Belgium | Participant |
| Roche Diagnostics International AG | Rotkreuz | Switzerland | Participant |
| Vseobecna Fakultni Nemocnice V Praze | Praha 2 | Czechia | Participant |
| Boehringer Ingelheim Internationalgmbh | Ingelheim | Germany | Participant |
| Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz | Mainz | Germany | Participant |
| Universitat Des Saarlandes | Saarbrucken | Germany | Participant |
| Evido Aps | Copenhagen | Denmark | Participant |
| Nordic Bioscience A/s | Herlev | Denmark | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Charokopeio Panepistimio | Athina | Greece | Participant |
| Fundacion Para La Gestion De La Investigacion En Salud De Sevilla | Sevilla | Spain | Third party |
| Servicio Andaluz De Salud | Sevilla | Spain | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Third party |
| Biocellvia SAS | Marseille | France | Participant |
| Echosens | Paris | France | Participant |
| Fondation Cardiometabolisme Nutrition | Paris | France | Participant |
| Consiglio Nazionale Delle Ricerche | Roma | Italy | Participant |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs | Roma | Italy | Third party |
| Universita Cattolica Del Sacro Cuore | Milano | Italy | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Boehringer Ingelheim B.V. | amsterdam | Netherlands | Associatedpartner |
| Elevate BV | Utrecht | Netherlands | Participant |
| Exit071 BV | Leiden | Netherlands | Participant |
| Julius Clinical Research BV | Zeist | Netherlands | Participant |
| Mimetas BV | Leiden | Netherlands | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Stichting Sint Franciscus Vlietlandgroep | Rotterdam | Netherlands | Participant |
| Stichting Wetenschappelijk Onderzoek Stichting Wetenschappelijk Onderzoek Franciscus | Rotterdam | Netherlands | Third party |
| Universiteit Leiden | Leiden | Netherlands | Participant |
| Universiteit Maastricht | Maastricht | Netherlands | Participant |
| Associação para Investigação e Desenvolvimento da Faculdade de Medicina | Lisbon | Portugal | Participant |
| Medical Education Research and Innovation Center S.r.l. | Bucuresti | Romania | Participant |
| European Atherosclerosis Society | Goteborg | Sweden | Participant |
| Mercodia Aktiebolag | Uppsala | Sweden | Participant |
| VLVbio AB | Stockholm | Sweden | Participant |
| Metadeq Limited | London | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI